Typical Testing Data/Standard Curve (for reference only)
Human ICOSL ELISA Kit | ICOSL elisa kit
ICOSL ELISA
Reactivity
Human
Applications
ELISA
Synonyms
ICOSL; ICOSL ELISA; ICOSL elisa kit
Reactivity
Human
Specificity
This ELISA is specific for the measurement of natural and recombinant human ICOSL [CD274].
Applicable Applications for ICOSL elisa kit
ELISA (EIA)
Samples
Cell culture supernatants, serum and plasma
Detection Range
0.0625 ng/ml - 4 ng/ml
Sensitivity
60 pg/ml
Intra-assay Precision
Four samples of known concentrations of human ICOSL were assayed in replicates 6 times to test precision within an assay.
Inter-assay Precision
Four samples of known concentrations of human ICOSL were assayed in 5 separate assays to test precision between assays.
Preparation and Storage
Store at 2-8 degree C
Typical Testing Data/Standard Curve (for reference only)
Typical Testing Data/Standard Curve (for reference only)
Related Product Information for ICOSL elisa kit
Intended Uses: The ICOSL (human) ELISA Kit is to be used for the in vitro quantitative determination of human ICOSL in cell culture supernatants, serum and plasma. This ELISA Kit is for research use only.
Background/Introduction: Inducible T-cell costimulatory protein (ICOS, also called CD278, AILIM, H4), a member of the CD28 family of costimulatory receptors, has a role in the generation and maintenance of germinal centers (GCs) in lymphatic organs, induction of thymus-dependent (TD) antibody (Ab) responses, and antibody class switching (1, 2). ICOS has a low expression on na.ve T cells but is rapidly induced on activated T cells (1, 2, 3). ICOS binds to the inducible co-stimulator ligand (ICOSL, also called CD275, B7-H2, B7h, B7RP-1) that is found in professional APCs such as dendritic cells (DCs), B lymphocytes, various non-hematopoietic cells such as endothelial cells (ECs), as well as some cancer cells (2, 4). ICOS activated by ICOSL induces T cell proliferation, survival and differentiation and co-induces the secretion of IL-4, IL-5, IL-6, IL-10, IL-21, TNF-alpha, and interferon gamma (IFN-gamma) (whereas CD28 induces IL-2 production) (5). Therefore, ICOS enhances Th1, Th2, and Th17 function largely through augmented production of these effector cytokines. ICOSL is upregulated by TNF-alpha and other inflammatory mediators and has an important co-stimulation role in EC (endothelial cells)-mediated T-cell activation, especially in reactivation of effector/memory T cells on the endothelium, which promote the homing of immune cells into inflamed tissue (5, 6). As seen in diverse types of costimulatory molecules in the CD28 family in T cells, ICOS is able to deliver a reverse signal through ICOSL that has a direct effect on dendritic cells (7). ICOS/ICOSL is involved in some hematologic malignancies such as myeloma or lymphoma. ICOS and its ligand ICOSL have been shown to play diverse roles in mediating autoimmunity as well as enhancing the development/activity of regulatory T cells (8). ICOS has a dual role in oncogenesis: i) the costimulatory signal of ICOS/ICOSL clearly participates in an antitumor T-cell response; ii) the ICOS signaling also exhibits pro-tumoral features, which are related to the induction of Treg immunosuppressive effects (9, 10, 11). In humans, homozygous ICOS deficiency results in common variable immunodeficiency (CVID), a condition characterized by aberrantly low serum gammaglobulin concentration (12). ICOS/ICOSL pathway is necessary for the optimal therapeutic effect of anti-CTLA-4, thus implicating this pathway as a target for future combinatorial strategies to improve the efficacy of anti-CTLA-4 therapy (13). ICOSL sheds from the cell membrane and the soluble form of ICOSL (sICOSL), found in plasma and sera, can be a potential biomarker for autoimmune diseases and some cancers (8).
Background/Introduction: Inducible T-cell costimulatory protein (ICOS, also called CD278, AILIM, H4), a member of the CD28 family of costimulatory receptors, has a role in the generation and maintenance of germinal centers (GCs) in lymphatic organs, induction of thymus-dependent (TD) antibody (Ab) responses, and antibody class switching (1, 2). ICOS has a low expression on na.ve T cells but is rapidly induced on activated T cells (1, 2, 3). ICOS binds to the inducible co-stimulator ligand (ICOSL, also called CD275, B7-H2, B7h, B7RP-1) that is found in professional APCs such as dendritic cells (DCs), B lymphocytes, various non-hematopoietic cells such as endothelial cells (ECs), as well as some cancer cells (2, 4). ICOS activated by ICOSL induces T cell proliferation, survival and differentiation and co-induces the secretion of IL-4, IL-5, IL-6, IL-10, IL-21, TNF-alpha, and interferon gamma (IFN-gamma) (whereas CD28 induces IL-2 production) (5). Therefore, ICOS enhances Th1, Th2, and Th17 function largely through augmented production of these effector cytokines. ICOSL is upregulated by TNF-alpha and other inflammatory mediators and has an important co-stimulation role in EC (endothelial cells)-mediated T-cell activation, especially in reactivation of effector/memory T cells on the endothelium, which promote the homing of immune cells into inflamed tissue (5, 6). As seen in diverse types of costimulatory molecules in the CD28 family in T cells, ICOS is able to deliver a reverse signal through ICOSL that has a direct effect on dendritic cells (7). ICOS/ICOSL is involved in some hematologic malignancies such as myeloma or lymphoma. ICOS and its ligand ICOSL have been shown to play diverse roles in mediating autoimmunity as well as enhancing the development/activity of regulatory T cells (8). ICOS has a dual role in oncogenesis: i) the costimulatory signal of ICOS/ICOSL clearly participates in an antitumor T-cell response; ii) the ICOS signaling also exhibits pro-tumoral features, which are related to the induction of Treg immunosuppressive effects (9, 10, 11). In humans, homozygous ICOS deficiency results in common variable immunodeficiency (CVID), a condition characterized by aberrantly low serum gammaglobulin concentration (12). ICOS/ICOSL pathway is necessary for the optimal therapeutic effect of anti-CTLA-4, thus implicating this pathway as a target for future combinatorial strategies to improve the efficacy of anti-CTLA-4 therapy (13). ICOSL sheds from the cell membrane and the soluble form of ICOSL (sICOSL), found in plasma and sera, can be a potential biomarker for autoimmune diseases and some cancers (8).
Similar Products
Product Notes
The Human ICOSL (Catalog #AAA490396) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. The AAA490396 ELISA Kit recognizes Human ICOSL. AAA Biotech's ICOSL can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA). Researchers should empirically determine the suitability of the ICOSL for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "ICOSL, ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
